Sarah Kotb
Assistant Professor of Economics, University of Utah
Department of Economics
University of Utah
Salt Lake City, UT
I am an Assistant Professor in the Department of Economics at the University of Utah. My research sits at the intersection of health and public economics, with a focus on how low-income Americans interact with the health insurance system and the safety net. I study why eligible individuals fail to enroll in the programs designed to help them, how the design of insurance and provider payment shapes access to care, and what these frictions mean for health, financial security, and inequality.
Much of my current work centers on Medicare and Medicaid — including take-up of the Medicare Savings Programs among low-income Medicare beneficiaries, the role of Federally Qualified Health Centers and the 340B drug pricing program in the primary care safety net, and the consequences of fragmented insurance coverage for dual-eligible populations.
I received my Ph.D. in Health Policy (Economics track) from Harvard University in 2025, where I was advised by Tim Layton, Anna Sinaiko, and Marcella Alsan. I was also an IvyPlus Visiting Student in Stanford’s Department of Health Policy, and before graduate school I was an Empirical Research Fellow at Stanford Law School.
You can reach me at sarah.kotb [at] utah.edu. My CV and Google Scholar are also linked here.
news
| Aug 01, 2026 | New working paper: The 340B Trade-Off between Affordable Drugs and Accessible Primary Care: Evidence from Federally Qualified Health Centers, with Ziping Ye and Amanda Su, now under review. |
|---|---|
| Oct 03, 2025 | Our paper on Medicare Savings Program take-up, with Amanda Su and Anna Sinaiko, is out in JAMA Network Open. |
| Jul 01, 2025 | I joined the Department of Economics at the University of Utah as an Assistant Professor. |
selected publications
- R&RSeparated at Birth: The Fragmentation of Health Insurance and Underinvestment in Preventative Care2026Revise and Resubmit, \em American Journal of Health Economics
- Under ReviewThe 340B Trade-Off between Affordable Drugs and Accessible Primary Care: Evidence from Federally Qualified Health Centers2026Under review